Targets › PCCB
1 program from 1 company in 2 trials: 2 Phase 1; Metabolic and endocrine; next expected readout Aug 2027.
This is one of the 2 subunits of the biotin-dependent propionyl-CoA carboxylase (PCC), a mitochondrial enzyme involved in the catabolism of odd chain fatty acids, branched-chain amino acids isoleucine, threonine, methionine, and valine and other metabolites. Propionyl-CoA carboxylase catalyzes the carboxylation of propionyl-CoA/propanoyl-CoA to D-methylmalonyl-CoA/(S)-methylmalonyl-CoA. Within the holoenzyme, the…. (UniProt, P05166)
Open in Phaseline: the race on PCCB, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| ModernaTX | mRNA-3927 mRNA therapy encoding propionyl-CoA carboxylase beta subunit | PCCB | Phase 1 | Propionic Acidemia | Aug 2027 |
Propionic Acidemia (2)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.